Genetic Technologies Limited (ASX:GTG, NASDAQ:GENE, OTC:GNTLF) has received A$1.75 million from the Australian Federal Government's Research and Development (R&D) Tax Incentive program for the 2023 financial year.
The capital infusion accounts for 43.5% of the company’s eligible R&D expenditure for the year, underscoring the government's support for innovation in the healthcare sector.
Genetic Technologies is a diversified molecular diagnostics enterprise, standing out as a global leader through its geneType and EasyDNA brands.
The company specialises in cancer predictive testing and offers tools for physician-assisted health outcome improvements worldwide.
About the company
The company leads in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands.
GTG offers cancer predictive testing and assessment tools to help physicians improve health outcomes for people around the world.
The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals.
Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.